NEWSROOM | Galderma

IMCAS 2026: Galderma showcases the latest scientific advances behind the industry’s broadest injectable aesthetics portfolio

IMCAS 2026: Galderma’s scientific presentations

Galderma provides update on arbitration case regarding neuromodulator research and development partnership

TOXINS 2026: Clinical updates on Galderma’s leading neuromodulator portfolio further reinforce its leadership in Injectable Aesthetics

TOXINS 2026: Galderma’s scientific presentations

New published data confirms Nemluvio® (nemolizumab) can rapidly relieve itch and improve sleep in as early as two days in both atopic dermatitis and prurigo nodularis

Prurigo nodularis: a long road to diagnosis

Galderma announces first patient enrollment in study to assess nemolizumab in adults with Chronic Pruritus of Unknown Origin

GAIN ASCENT Summit, our training program for emerging injectors, marks the end of GAIN's first decade

Galderma welcomes increased equity investment from L’Oréal

Galderma opens up new chapter for Sculptra® with MDR certification and new expanded indication for body

Galderma secures ‘BBB’ credit rating with positive outlook from S&P Global Ratings

ASDS 2025: Compelling new data on Restylane, Sculptra and Relfydess highlight Galderma’s innovative Injectable Aesthetics portfolio and pipeline